Drug intelligence / Profile preview

ricolinostat + pomalidomide + dexamethasone

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy consisting of ricolinostat (ACY-1215), pomalidomide, and dexamethasone. Ricolinostat is a selective histone deacetylase 6 (HDAC6) inhibitor developed to enhance anti-myeloma activity when combined with other agents. Pomalidomide is an immunomodulatory agent that inhibits angiogenesis and myeloma cell growth, acting as a cereblon E3 ligase modulator. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. This combination has been investigated in relapsed or refractory multiple myeloma, showing improved response rates compared to standard regimens[1][4][5].

Brand names: Pomalyst
Other names: ricolinostatpomalidomidedexamethasone

Targets

HDAC6 (Histone deacetylase 6)CRBN (Cereblon)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on ricolinostat + pomalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ricolinostat + pomalidomide + dexamethasone.

Explore the full profile